CAR-T treatment failure patients can also completely mitigate the results of dual-specific antibody clinical trials positive

B-NHL includes types such as diffuse large B-cell lymphoma (DLBCL) and ostosis (FL)DLBCL is a rapidly developing B-NHL, with up to 50% of advanced patients developing disease after first-line therapy, and R/R DLBCL patients have limited treatment options and poor prognosisFL is a slow B-NHLAlthough the median survival of patients with advanced FL is 8-15 years, the current treatment options are not curable, and most patients return within 5 years of treatmentIn some cases, FL evolves into DLBCLREGN1979 is a targeted CD20 and CD3 bispecific antibody generated using a unique Veloci-Bi bispecific antibody platform of Regenerative ElementThis technology platform is capable of producing full-length bispecific antibodies similar to natural antibodiesNot only can be manufactured using standard antibody production techniques, but also have pharmacokinetic properties similar to antibodyREGN1979 aims to attack tumor cells near tumor cells that express CD20 by binding to CD3 antigens on the surface of T cellsIt has been granted an FDA-granted status for orphan drugsresults in the eHA study showed:in R/R FL patients with levels of 1 to 3a, the total remission rate reached 93% (13/14), of which the total remission rate reached 71%in R/R DLBCL patients, 2 of the 3 patients who did not receive CAR-T therapy achieved complete remission, and 2 of the 4 patients who had been treated with CAR-T therapy with targeted CD-19 and continued to develop the disease"REGN1979 is encouraged by the high remission rates shown in R/R DLBCL and FL patientsThese patients are usually poor lygbine," said DrIsrael Lowy, Senior Vice President of Regeneration And Head of Oncology clinical and translational scienceOur potentialregister Phase 2 clinical trial will be launched this month to assess the efficacy of REGN1979 in patients with inert and invasive non-Hodgkin's lymphoma References: Retrieved June 14, 2019, from https://